Chief: Julie Vose, M.D., MBA
Administrator: Lisa Muschall
Division Personnel:
- Faculty: 17 (16 clinical M.D.s and 1 research M.D.)
- Fellows: 6
- Staff: 57
New Faculty:
- Matthew Lunning, D.O., assistant professor, started July 1, 2013. Dr. Lunning specializes in the diagnosis and treatment of rare lymphoid malignancies, multiple myeloma and benign hematologic conditions. He sees patients in the main campus cancer center and Village Pointe. He attends on transplant service and hematology consult service.
- Krishna Gundabolu, M.B.B.S., assistant professor, started Jan. 1, 2014. Dr. Gundabolu treats benign hematology and thrombosis patients. He has clinics at the main campus cancer center and Village Pointe. His research interests include thrombosis, myelodysplastic syndrome, immunology and stem cell biology.
Research:
The Division of Oncology/Hematology has a long tradition of pioneering research in the field of cancer and its treatment. There are numerous ongoing state-of-the art clinical trials that are available to patients with various cancers to include lymphoma, leukemia, breast, lung, gastrointestinal and genitourinary malignancies, neuro-oncology, melanoma, sarcoma, bone marrow and peripheral stem cell transplants, thrombosis and non-malignant hematology. Funding for clinical trials comes from many resources including NIH, NCI, NHLBI, NCCN and pharmaceutical companies.
The division currently has 71 actively accruing clinical trials:
- 19 multi-site and investigator initiated (includes 5 non-therapeutic banking and registry trials)
- 21 cooperative group
- 3 BMT clinical trials network
- 28 industry-sponsored
We are a core center involved in the Blood and Marrow Transplant Clinical Trial Network (BMT CTN). The BMT CTN is funded by the National Cancer Institute and is a network of transplant centers in the U.S. actively recruiting patients to various clinical protocols in stem cell transplantation.
We are a main member site for the cooperative group, Alliance for Clinical Trials in Oncology (Alliance). Alliance is part of a national clinical trials network sponsored by the National Cancer Institute. The group consists of nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. Alliance seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.
The division also is a member of Academic and Community Cancer Research United (ACCRU). ACCRU is a clinical research network that brings together leading scientific researchers from more than 65 academic institutions and community-based cancer treatment practices in the United States and Canada committed to developing and conducting high quality cancer research that will improve the duration and quality of life for cancer patients and improve the understanding of cancer biology and biological consequences of cancer treatment.
Clinical:
We are pleased to offer patients access to a full team of cancer specialists, providing a comprehensive individual approach to care that includes medical oncologists, hematologists, advanced practice providers, case managers and oncology certified nurses. We practice a multidisciplinary approach and focus on each patient’s best possible outcome. New patient coordinators contact patients and other medical offices to gather all necessary information prior to the patient’s initial appointment.
Clinic Locations:
The Nebraska Medical Center main campus
Peggy D. Cowdery Patient Care Center
42nd & Emile St. (Lied Transplant Center, 3rd floor)
Omaha, NE 68198
402-559-5600
Monday-Friday, 8 a.m. – 5 p.m.
The Nebraska Medical Center Cancer Center at Village Point
111 N. 175th St.
Omaha, NE 68118
402-596-3100
Monday-Friday, 8 a.m. – 5 p.m.
Oncology at Bellevue Medical Center
2510 Bellevue Medical Center
Omaha, NE 68123
402-559-5600
Monday-Friday, 8 a.m. – 5 p.m.
New Program:
Cancer Wellness
The division recently revised the cancer survivorship program and renamed it the Wellness Program. Once patients complete their course of treatment, the transition back to everyday life and routines can be stressful. This program aims to help smooth that transition for patients. The goal is for all patients to live life to the fullest during treatment and beyond. A team of mid-level providers works alongside the physicians to support the patient throughout all phases of care.
Throughout treatment a mid-level provider will review patient progress. Based on patient need, the patient will receive guidance and/or referral to the appropriate health care provider to meet their specific need as it relates to nutrition, exercise/physical therapy, psychology, psychiatry, social work, etc.
When patients complete their chemotherapy and/or radiation treatment, a mid-level will provide a one-time evaluation and help create a survivorship plan and provide recommendations for long term follow-up care.
Each patient is given a comprehensive treatment summary for their records. This summary also is sent to the patient’s primary care physician. In addition, the mid-level will:
- Review recent medical history and complete a physical examination
- Assess the patient to detect recurrence of cancer
- Provide identification and management of the effects of cancer and its treatment
- Provide screening referrals for other cancers
- Provide health promotion recommendations related to nutrition, exercise, and smoking cessation
- Provide a treatment summary and follow-up care plan
2013/2014 Publications:
Accolades:
James Armitage, M.D., is the recipient of the 2014 ASCO Special Recognition Award which honors achievements of an individual whose research and innovations have had a transforming and lasting effect in areas of clinical oncology, cancer research, clinical trials, and patient advocacy activities or outstanding long-term service to ASCO and/or to clinical oncology.
Julie Vose, M.D., M.B.A., was recently awarded Fellow of the American Society of Clinical Oncology (FASCO) distinction which recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the patients they serve.
Julie Vose, M.D., M.B.A., FASCO, was elected president of the American Society of Clinical Oncology (ASCO) for 2015-2016. She will begin duties as president-elect in June 2014.
Apar Ganti, M.D., was recently elected to the board of directors of Academic and Community Cancer Research United (ACCRU), a clinical research network that brings together leading scientific researchers from more than 65 academic institutions and community-based cancer treatment practices in the United States and Canada.
Julie Vose, M.D., M.B.A., FASCO, will be honored by the Women’s Center for Advancement (WCA) at its annual Tribute to Women event in June 2014. A Tribute to Women Award is considered to be one of the most prestigious honors in Omaha. Honorees have demonstrated a lifelong commitment to helping women and their children stay safe and grow strong.